Search Within

Dhwani Patel

Formats
  1. Meeting Abstract (33)
  2. Journal Article (8)
  3. Research Letter (2)
Groups
  1. CTCR Scholars (43)
  2. Center for Hematologic Malignancies (43)
  3. Department of Medicine (43)
  4. General Medicine Services (43)
  5. Hematologic Malignancies, Division of (43)
  6. Hospital Medicine (43)

More Groups

People
  1. Alexander Lesokhin (42)
  2. Carlyn Rose Tan (42)
  3. Hani Hassoun (42)
  4. Malin Hultcrantz (42)
  5. Neha Korde (42)
  6. Sham Mailankody (42)

More People

Years
  1. 2025 (2)
  2. 2024 (7)
  3. 2023 (14)
  4. 2022 (12)
  5. 2021 (4)
  6. 2020 (4)
Publications
  1. Blood (18)
  2. Clinical Lymphoma, Myeloma and Leukemia (11)
  3. Journal of Clinical Oncology (4)
  4. Blood Advances (3)
  5. Blood Cancer Journal (2)
  6. Blood Cancer Discovery (1)

More Publications

Publishers
  1. American Society of Hematology (21)
  2. Elsevier Inc. (11)
  3. American Society of Clinical Oncology (4)
  4. Nature Publishing Group (3)
  5. American Association for Cancer Research (2)
  6. Ferrata Storti Foundation (1)

More Publishers

Results (43)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Bispecific T-cell engager response is driven by pre-treatment CD8+ effector memory cells and inhibited by TIGIT+ Tregs in relapsed/refractory multiple myeloma
    Meeting Abstract

    Firestone, R.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I.; Wang, A.; Zhu, M.; Patel, D.; Tan, C. R.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies
    Meeting Abstract

    Firestone, R.; Shekarkhand, T.; Patel, D.; Tan, C. R. C.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Korde, N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Journal Article

    Tan, C. R.; Derkach, A.; Nemirovsky, D.; Ciardiello, A.; Diamond, B.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Maclachlan, K.; more...
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save
  • Bone remineralization of lytic lesions in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib, lenalidomide, dexamethasone +/- daratumumab induction regimen
    Meeting Abstract

    Meseha, M.; Abusamra, M.; Farooki, A.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Shah, U.; Lu, S.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Evaluating serum free light chain ratio as a biomarker for multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Lu, S.; Patel, D.; Shah, U.; Tan, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • African American patients with smoldering multiple myeloma may have a lower risk of progression compared to white patients
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Lu, S.; Patel, D.; Shah, U.; Tan, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real-world single center experience
    Meeting Abstract

    Hultcrantz, M.; Derkach, A.; Hassoun, H.; Korde, N.; Maclachlan, K. H.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C.; Akhlaghi, T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A pilot plant based dietary intervention in MGUS and SMM patients with elevated BMI is feasible and associated with improvements in metabolic and microbiome biomarkers of progression
    Meeting Abstract

    Shah, U. A.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Tran, L.; Adintori, P. A.; Burge, M.; Funkhouser, S.; Hosszu, K.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 2 trial of colesevelam for lenalidomide-associated diarrhea
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Korde, N.; Mailankody, S.; Shekarkhand, T.; Burge, M.; Maclachlan, K. H.; Patel, D.; Shah, U. A.; Chung, D. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Carfilzomib, lenalidomide and dexamethasone (KRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) as induction therapy in newly diagnosed high-risk multiple myeloma
    Meeting Abstract

    Tan, C.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Patel, D.; Maclachlan, K. H.; Lahoud, O. B.; more...
    Blood (2022)

    Fulltext@MSK | Save